Orchestra BioMed Holdings, Inc.
OBIOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 5, 2026 | H.C. Wainwright | Yi Chen | $10.00(+68%) | $5.95 | StreetInsider |
| Sep 10, 2026 | BTIG | Marie Thibault | $10.00(+83%) | $5.45 | TheFly |
| Aug 11, 2026 | Piper Sandler | Matt O'Brien | $10.00(+124%) | $4.46 | TheFly |
| May 13, 2026 | Barclays | Matt Miksic | $13.00(+220%) | $4.06 | TheFly |
| Jan 9, 2026 | Barclays | Matt Miksic | $12.00(+148%) | $4.84 | TheFly |
| Mar 20, 2025 | BTIG | Marie Thibault | $12.00(+176%) | $4.35 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Oct 23, 2026 |
| B. Riley Securities | maintain | Buy | Sep 15, 2026 |
| BTIG | upgrade | Neutral →Buy | Sep 10, 2026 |
| Piper Sandler | maintain | Overweight | Aug 11, 2026 |
| B. Riley Securities | maintain | Buy | May 19, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2026 |
| Barclays | maintain | Overweight | May 13, 2026 |
| Chardan Capital | maintain | Buy | Mar 12, 2026 |
| Barclays | maintain | Overweight | Jan 9, 2026 |
| Chardan Capital | maintain | Buy | Nov 13, 2025 |
| Barclays | maintain | Overweight | Nov 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 4, 2025 |
| BTIG | downgrade | Buy →Neutral | Aug 20, 2025 |
| Chardan Capital | maintain | Buy | Aug 13, 2025 |
| Chardan Capital | maintain | Buy | Aug 7, 2025 |
| Chardan Capital | maintain | Buy | May 13, 2025 |
| Barclays | maintain | Overweight | May 5, 2025 |
| Chardan Capital | maintain | Buy | Apr 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| Chardan Capital | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| Chardan Capital | maintain | Buy | Nov 13, 2024 |
| Chardan Capital | maintain | Buy | Jun 12, 2024 |
| Chardan Capital | maintain | Buy | Mar 28, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.38 | $-0.39 | $88.0K | $137.7K |
| May 12, 2026 | $-0.33 | $-0.40 | $110.0K | $918.7K |
| Mar 12, 2026 | $0.12 | $-0.38 | $30.9M | $931.0K |
| Nov 10, 2025 | $-0.40 | $-0.38 | $861.0K | $741.4K |
| Aug 12, 2025 | $-0.50 | $-0.51 | $836.0K | $778.8K |
| Apr 2, 2025 | $-0.43 | $-0.43 | $253.0K | $522.3K |
| Mar 26, 2025 | $-0.37 | $-0.43 | $253.0K | — |
| Nov 12, 2024 | $-0.41 | $-0.44 | $987.0K | $703.3K |
News
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $5.00 per share (the “Offering”).
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB's mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons.
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City.
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” o…
TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital.
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy ("AVIM Therapy") will be featured in two sessions at HRX Live 2026 -- the Heart Rhythm Society's annual innovation-focused …
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides additional capital to advance Orchestra BioMed's pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holding…
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 133,000 shares of the Company's common stock t…
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C.
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9.
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago.